While SHP2 mutations are found in certain hematological malignancies, the rationale for drugging SHP2 is often because of its location at the interface of transmembrane RTKs and intracellular signal transduction pathways (i.e., MAPK, JAK/STAT, PI3K-AKT) [325, 326]. This evidence concerns the gene PTPN11 and hematologic disorder.